| Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights |
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. “As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. |
globenewswire.com |
2025-05-13 11:30:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights |
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 |
globenewswire.com |
2025-03-26 09:30:00 |
Czytaj oryginał (ang.) |
| MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? |
MEREO BIOPHARMA (MREO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-20 15:00:30 |
Czytaj oryginał (ang.) |
| Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential |
Stocks priced under $10 present an attractive entry point into the market for investors seeking to maximize portfolio diversification and growth potential without a significant upfront capital outlay. These affordable equities allow investors to acquire a larger number of shares for a given investment and can yield substantial percentage gains. |
marketbeat.com |
2025-03-11 09:16:29 |
Czytaj oryginał (ang.) |
| Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference |
LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT. |
globenewswire.com |
2025-03-05 09:30:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Provides Update on Lead Clinical Programs |
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 |
globenewswire.com |
2025-01-12 13:05:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 8:15am PT / 04:15pm GMT. |
globenewswire.com |
2025-01-07 09:30:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points |
Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from the phase 2/3 ORBIT study indicates a significant reduction in fracture rates, bolstering confidence in ongoing phase 3 trials. Financially stable with $87.4 million in cash, Mereo aims to secure a partner for Alvelestat's phase 3 trial, potentially boosting stock value. |
seekingalpha.com |
2024-11-26 15:36:23 |
Czytaj oryginał (ang.) |
| Verde Reports up to 13,944 ppm TREO 5,222 ppm MREO and 213 ppm DyTb |
Results from 16 new holes show a thick mineralized zone up to 74m with grades up to 4,321 ppm TREO and 1,004 ppm MREO Results from 16 new holes show a thick mineralized zone up to 74m with grades up to 4,321 ppm TREO and 1,004 ppm MREO |
globenewswire.com |
2024-11-18 09:00:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference |
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT. |
globenewswire.com |
2024-11-14 09:30:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $80.5 million as of September 30, 2024, which the Company believes will provide runway into 2027, through multiple key inflection points. |
globenewswire.com |
2024-11-12 09:30:00 |
Czytaj oryginał (ang.) |
| Verde's assays of over 1,500m of drilling find rare earths up to 12,487 ppm TREO and 3,357 ppm MREO |
Results from 13 new holes show an 89m thick mineralized zone with grades up to 3,706 ppm TREO and 839 ppm MREO Results from 13 new holes show an 89m thick mineralized zone with grades up to 3,706 ppm TREO and 839 ppm MREO |
globenewswire.com |
2024-10-29 09:15:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference |
LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST. |
globenewswire.com |
2024-09-12 21:35:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $87.4 million as of June 30, 2024, which includes the net proceeds of the Company's $50 million registered direct offering in June 2024. |
globenewswire.com |
2024-08-13 12:00:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market |
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to be used to fund the setrusumab program, including supply and pre-launch activities in Europe, and for working capital and other general corporate purposes. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-06-14 11:50:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference |
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST. |
globenewswire.com |
2024-05-30 11:30:00 |
Czytaj oryginał (ang.) |
| Equities Analysts Offer Predictions for Mereo BioPharma Group plc’s Q2 2024 Earnings (NASDAQ:MREO) |
Mereo BioPharma Group plc (NASDAQ:MREO – Free Report) – Equities researchers at Leerink Partnrs issued their Q2 2024 earnings per share estimates for shares of Mereo BioPharma Group in a report released on Wednesday, May 15th. Leerink Partnrs analyst J. Schwartz forecasts that the company will earn ($0.01) per share for the quarter. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is $0.03 per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings at $0.16 EPS and FY2025 earnings at $0.03 EPS. MREO has been the subject of a number of other research reports. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Mereo BioPharma Group in a research report on Thursday. Get Our Latest Report on Mereo BioPharma Group Mereo BioPharma Group Stock Performance Shares of Mereo BioPharma Group stock opened at $3.20 on Monday. The business has a 50-day moving average price of $3.04 and a 200-day moving average price of $2.90. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.72 and a current ratio of 6.72. Mereo BioPharma Group has a twelve month low of $0.92 and a twelve month high of $4.36. Institutional Trading of Mereo BioPharma Group Institutional investors have recently added to or reduced their stakes in the company. Advisors Preferred LLC bought a new stake in Mereo BioPharma Group in the first quarter worth about $28,000. SG Americas Securities LLC bought a new stake in Mereo BioPharma Group in the first quarter worth about $54,000. BNP Paribas Financial Markets lifted its stake in Mereo BioPharma Group by 581,066.7% in the first quarter. BNP Paribas Financial Markets now owns 17,435 shares of the company’s stock worth $58,000 after purchasing an additional 17,432 shares during the last quarter. Golden State Equity Partners lifted its stake in Mereo BioPharma Group by 41.0% in the fourth quarter. Golden State Equity Partners now owns 20,300 shares of the company’s stock worth $47,000 after purchasing an additional 5,900 shares during the last quarter. Finally, Index Fund Advisors Inc. bought a new stake in Mereo BioPharma Group in the first quarter worth about $99,000. Institutional investors own 62.83% of the company’s stock. About Mereo BioPharma Group (Get Free Report) Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. |
https://www.defenseworld.net |
2024-05-20 05:38:48 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update |
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. |
globenewswire.com |
2024-05-15 20:01:00 |
Czytaj oryginał (ang.) |
| MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-04-12 14:36:10 |
Czytaj oryginał (ang.) |
| Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference |
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST. |
globenewswire.com |
2024-04-03 11:30:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update |
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively |
globenewswire.com |
2024-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032 |
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference. |
seekingalpha.com |
2024-03-14 19:34:14 |
Czytaj oryginał (ang.) |
| Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference |
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 11:20am ET / 03:20pm GMT. |
globenewswire.com |
2024-03-05 09:30:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments |
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 |
globenewswire.com |
2024-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update |
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information. |
globenewswire.com |
2023-10-23 20:01:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference |
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST. |
globenewswire.com |
2023-09-21 11:00:00 |
Czytaj oryginał (ang.) |
| Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update |
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim financial results for the six months ended June 30, 2023 and provided an update on recent corporate highlights. |
globenewswire.com |
2023-09-07 11:30:00 |
Czytaj oryginał (ang.) |